Oxidation of Analogs of l‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine by Monoamine Oxidases A and B and the Inhibition of Monoamine Oxidases by the Oxidation Products

Abstract: Twenty analogs of l‐methyl‐4‐phenyl‐l,2,3,6‐tet‐rahydropyridine (MPTP) were tested for their capacity to be xidized by pure monoamine oxidase‐A (MAO‐A) prepared from human placenta and pure monoamine oxidase‐B (MAO‐B) prepared from beef liver. Several of the MPTP analogs were very good substrates for MAO‐A, for MAO‐B, or for both and had low Km values and high turnover numbers. These values were similar to or even better than those of kynuramine and benzylamine, good substrates for MAO‐A and MAO‐B, respectively. MPTP had relatively low Km values for oxidation by both MAO‐A and MAO‐B. In contrast, the turnover number for MPTP oxidation by MAO‐B was considerably higher than the value for MAO‐A. The corresponding pyridinium species of MPTP and several of the MPTP analogs inhibited MAO‐A competitively with Ki values at micromolar concentrations; in contrast the pyridinium species inhibited MAO‐B competitively at considerably higher concentrations (i.e., 100 μM or greater Ki values). The data provide information concerning the structural requirements for the oxidation of tetrahydropyridines by MAO‐A and MAO‐B and the inhibition of these enzymes by pyridini‐ums

[1]  P. Sonsalla,et al.  Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Harik,et al.  Potent Neurotoxic Fluorinated 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Analogs as Potential Probes in Models of Parkinson Disease , 1988, Journal of neurochemistry.

[3]  R. Ramsay,et al.  Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[4]  R. Heikkila,et al.  Evaluation of the Biological Activity of Several Analogs of the Dopaminergic Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[5]  N. Castagnoli,et al.  Cation-exchange high-performance liquid chromatography assay for the nigrostriatal toxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B generated metabolites in brain tissues. , 1987, Journal of chromatography.

[6]  N. Castagnoli,et al.  Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. , 1986, The Biochemical journal.

[7]  A. Brossi,et al.  Interaction of monoamine oxidase B with analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine derived from prodine-type analgesics. , 1986, Journal of medicinal chemistry.

[8]  J. D. de Vries,et al.  Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues. , 1986, Journal of medicinal chemistry.

[9]  L. Peterson,et al.  Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, Journal of medicinal chemistry.

[10]  A. Brossi,et al.  Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B , 1985, FEBS letters.

[11]  T. Singer,et al.  Reversible inhibition and mechanism-based irreversible inactivation of monoamine oxidases by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, Biochemical and biophysical research communications.

[12]  N. Castagnoli,et al.  Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.

[13]  M. Yahr,et al.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.

[14]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[15]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[16]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[17]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[18]  W. Weyler,et al.  Iron content and spectral properties of highly purified bovine liver monoamine oxidase. , 1981, Archives of biochemistry and biophysics.

[19]  C. J. Schmidle,et al.  The Aminomethylation of Olefins. V. A New Synthesis of 4-Phenylpyridine and Related Compounds , 1956 .

[20]  C. J. Schmidle,et al.  The Aminomethylation of Olefins. IV. The Formation of 1-Alkyl-4-aryl-1,2,3,6-tetrahydropyridines , 1956 .